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Abstract   
Background:  We previously reported high-throughput RNA sequencing analyses that identified 
heightened expression of the chromatin architectural factor High Mobility Group AT-hook 1 
(HMGA1) in pulmonary arterial (PA) endothelial cells (ECs) from idiopathic PA hypertension 
(IPAH) patients compared to controls.  Since HMGA1 promotes epithelial to mesenchymal 
transition in cancer, we hypothesized that increased HMGA1 could induce transition of PAECs 
to a smooth muscle (SM)-like mesenchymal phenotype (EndMT), explaining both dysregulation 
of PAEC function and possible cellular contribution to the occlusive remodeling that 
characterizes advanced IPAH.   
Methods and Results:  We documented increased HMGA1 in PAEC cultured from IPAH vs. 
donor control lungs.  Confocal microscopy of lung explants localized the increase in HMGA1 
consistently to PA endothelium, and identified many cells double-positive for HMGA1 and 
smooth muscle 22 alpha (SM22α) in occlusive and plexogenic lesions.  Since decreased 
expression and function of bone morphogenetic protein receptor (BMPR)2 is observed in PAH, 
we reduced BMPR2 by siRNA in control PAECs and documented an increase in HMGA1 
protein.  Consistent with transition of PAECs by HMGA1, we detected reduced PECAM-1 
(CD31) and increased EndMT markers, αSMA, SM22α, calponin, phospho-vimentin and Slug. 
The transition was associated with spindle SM-like morphology, and the increase in αSMA was 
largely reversed by joint knockdown of BMPR2 and HMGA1 or Slug.  Pulmonary ECs from 
mice with EC-specific loss of BMPR2 showed similar gene and protein changes.  
Conclusions:  Increased HMGA1 in PAECs resulting from dysfunctional BMPR2 signaling can 
transition endothelium to SM-like cells associated with PAH. 
Key Words: HMGA1, Endothelial-to-Mesenchymal Transition, Pulmonary Hypertension  
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Introduction  
Pulmonary arterial hypertension (PAH), whether idiopathic (IPAH), heritable (HPAH) or 
associated with other conditions (APAH) is a potentially lethal disease characterized by 
progressive vascular changes leading to obliteration of distal pulmonary arteries (PAs)1.  
Abnormal muscularization and loss of pre-capillary PAs is followed by proliferation of vascular 
cells in more proximal PAs to form an occlusive neointima2.  The origin of the neointimal cells 
remains unclear; they were originally thought to be derived from the muscular media as they 
express alpha smooth muscle actin (αSMA)3.  However dysfunctional endothelial cells (ECs) 
could, by endothelial-to-mesenchymal transition (EndMT)4,5 contribute to neointima formation 
either directly, or indirectly by transforming in a way that impedes their ability to produce factors 
such as apelin that control smooth muscle cell (SMC) proliferation6. 
 
EndMT is a process by which endothelial cells acquire a mesenchymal phenotype in association 
with expression of SMC genes, such as αSMA4 and phospho(p) vimentin, and reduction in 
endothelial genes such as VE-cadherin and PECAM-1 (CD144 and CD31, respectively).  
Endothelial fate-mapping in a mouse model of pulmonary hypertension demonstrated cells of 
endothelial lineage expressing SMC markers that contribute to the neointima7.  Pulmonary artery 
endothelial cells (PAECs) can acquire a smooth muscle phenotype in culture in a transforming 
growth factor beta (TGFβ)-dependent manner8,9.  While EndMT has been implicated in the 
human pathology of PAH5, the initiating factor and the pathway involved have not been 
described. 
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Our group applied high throughput RNA sequencing to PAECs obtained from lungs of patients 
with PAH or from donor controls, and observed elevated mRNA expression of High Mobility 
Group AT-hook 1 (HMGA1) in the patients10.  This gene is a member of a family of architectural 
factors that bind AT-rich regions of DNA and alter the chromatin structure to influence 
transcriptional activity11.  HMGA1 is highly expressed in stem cells during embryonic 
development, but as tissues mature HMGA1 levels drop and are very low in fully differentiated 
tissues11.   Abnormal elevation in HMGA1 contributes to neoplastic transformation in multiple 
cancers12–14 by inducing epithelial-to-mesenchymal transition (EMT)12.  An invasive phenotype 
results from repression of the epithelial junction protein E-cadherin and up-regulation of 
mesenchymal genes.  These features completely reverse with loss of HMGA114.  Snail and Slug 
(Snai1 and Snai2, respectively) are closely related zinc finger transcription factors that have been 
implicated in EMT and EndMT15–17.  HMGA2, a protein closely related to HMGA1, can directly 
affect expression of Snail by binding the promoter and recruiting SMAD proteins to increase 
transcription of the SNAI1 gene18. 
 
BMPR2 mutations are found in approximately 70% of patients with heritable PAH and 20% of 
sporadic cases or IPAH19,20, and even IPAH patients without known BMPR2 mutations have 
reduced expression of BMPR2, as do patients with APAH21.  Silencing BMPR2 in control 
PAECs causes an elevation in expression of HMGA1 that is phenocopied by reducing levels of 
β-catenin, an effector of gene regulation downstream of BMPR210.  We therefore hypothesized 
that dysfunctional BMPR2 signaling in PAH PAECs causes an elevation in HMGA1, promoting 
acquisition of a mesenchymal phenotype via a process of EndMT.  
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Materials and Methods  
Subjects and human primary cell culture:  As previously described22, we harvested and cultured  
ECs predominantly from small (<1mm) PAs.  We analyzed tissue sections from explanted lungs 
of patients with IPAH and HPAH, obtained at time of transplantation, and from unused donor 
control lungs, via the Pulmonary Hypertension Breakthrough Initiative (PHBI) Network, funded 
by the Cardiovascular Medical and Education Fund (CMREF) and NIH-NHLBI.  Demographic 
and clinical data relevant to PAH patients and controls are in Table 1.  PAECs from lung tissues 
were grown in commercial EC media containing 5% FBS (Sciencell, Carlsbad, CA) and used at 
passages 3-622 as were commercial human PAECs (PromoCell, Heidelberg, Germany). 
 
siRNA transfection:  siRNAs for BMPR2, HMGA1, Slug and non-targeting control siRNAs 
(GE Healthcare Dharmacon, Lafayette, CO) were transfected into subconfluent PAECs at a 
concentration of 20nM using Lipofectamine RNAiMAX and OptiMEM medium (Life 
Technologies, Carlsbad, CA).  We measured gene expression (mRNA) at 72h and protein levels 
at seven days. In some experiments, PAECs were transfected with control non-targeting siRNA, 
incubated for 48h, and then treated with TGFβ2 (Abcam, Cambridge, MA) for five days.  
 
Quantitative RT-PCR: RNA was extracted using a spin column-based kit (Zymo Research, 
Irvine, CA) and quantified using a spectrophotometer.  Quantitative RT-PCR (qPCR) was 
performed on a CFX384 Real Time System (BioRad, Hercules, CA) using 4ng cDNA, 1mM 
primers, and a SybrGreen master mix (Life Technologies).  Primer sequences, designed using 
NCBI’s Primer-BLAST function, are shown in Supplementary Table 1. 
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Immunoblotting:  Protein samples were separated by SDS-PAGE on 4-12% Bis-Tris gradient 
gels (Life Technologies), transferred onto nitrocellulose membranes (Bio-Rad), and incubated 
with primary antibodies, diluted 1:1,000 (unless noted): rabbit anti-HMGA1 (1:10,000), rabbit 
anti-vimentin (1:4,000), mouse anti-phospho vimentin (1:250), mouse anti-PECAM-1, rabbit 
anti-Snail/Slug, rabbit VE-cadherin, goat anti-SM22α (Abcam), mouse anti-αSMA (Sigma-
Aldrich, St Louis, MO), mouse anti-GAPDH, mouse anti-β-actin (Santa Cruz Biotechnology, 
Dallas, TX), and mouse anti-BMPR2 (1:200, BD Biosciences, Franklin Lakes, NJ).  
 
Immunohistochemistry:  Formaldehyde-fixed, paraffin-embedded tissue sections were stained 
as previously described22, using an HMGA1 antibody (1:500, Abcam) and anti-rabbit secondary 
antibody 3,3′-diaminobenzidine (Dako, Carpinteria, CA), and counterstained with hematoxylin.  
 
Immunofluorescence:  Tissue sections were processed as described above and incubated with 
antibodies against HMGA1 (1:500, Abcam), von Willebrand Factor (1:100, Abcam) and 
SM22α (1:100, Abcam).  Nuclei were stained with DRAQ7 (Biostatus, UK).  PAECs were 
cultured in chamber slides, fixed in 4% paraformaldehyde and permeabilized using 0.1% Triton 
X-100 (Sigma-Aldrich).  Slides were incubated with primary antibodies against αSMA (1:200, 
Sigma-Aldrich) and VE-cadherin (1:150, Abcam).  Fluorescent-tagged secondary antibodies 
were used at 1:400 (Life Technologies).  Slides were mounted using Vectashield with or without 
DAPI (Vector Laboratories, Burlingame, CA) and imaged using a confocal microscope 
(Olympus, Center Valley, PA and Leica, Buffalo Grove, IL). 
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Transgenic Mice:  The Animal Care Committee of Stanford University approved all protocols. 
Mice with an endothelial-specific inducible knockout of BMPR2 were created in our laboratory 
(SCL-CreERTM+/R26R/Bmpr2-/-)23.  Wild-type mice were used as controls.  Murine pulmonary 
ECs were isolated from digested whole lung tissue using CD31 antibody-coated magnetic beads 
(Dynabeads; Invitrogen) as previously described6. 
 
Statistical Analysis:  Values from multiple experiments are depicted in box plots showing 
minimum, maximum and the median for each experiment. When values are depicted in 
scatterplots, the lines represent the mean±SEM. The number of experiments, IPAH or control 
cells used are indicated in the figure legends.  Statistical significance was determined using one-
way ANOVA followed by Bonferroni’s multiple comparisons test or by Kruskal-Wallis test 
followed by Dunn’s post hoc test, as indicated in the figure legends.  When only two groups 
were compared, statistical differences were assessed with unpaired two-tailed Student’s t-test.	  A 
p-value of <0.05 was considered significant.  
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Results 
HMGA1 is elevated in PAECs from patients with PAH relative to controls 
We observed elevated HMGA1 protein in PAECs (passage 3-6) from HPAH patients with a 
BMPR2 mutation compared to those from donor control lungs and a similar trend in PAECs 
from IPAH patients (Fig 1A).  HMGA1 immunoperoxidase staining was prominent in the PA 
endothelium of lung tissue sections from IPAH patients whereas immunoreactivity was barely 
detectable in control PA endothelium (Fig 1B).  While HMGA1 was localized to the 
endothelium primarily, HMGA1 positive cells also appeared in the neointima, often close to the 
endothelial surface of the occluded vessels (Fig 1C).  HMGA1 immunoreactivity was increased 
in PAs of all sizes in PAH vs. control lungs and in all lesions including plexiform lesions, (Fig 
1C, D).  
 
To determine whether HMGA1 was co-expressed with endothelial and/or SM markers in IPAH 
PAs, we performed confocal microscopy on lung tissue sections using immunofluorescence 
staining.  In vessels of different sizes from PAH patients, HMGA1 appeared to co-localize 
predominantly with the endothelial marker von Willebrand Factor (vWF) but also with smooth 
muscle 22 alpha (SM22α) positive cells in the neointima (Fig 2).  HMGA1 expression was much 
less intense in control tissues.  
 
Loss of BMPR2 induces elevation of HMGA1 and changes consistent with EndMT 
To mimic BMPR2 loss in PAH patients, we transfected BMPR2 siRNA in control PAECs and 
evaluated whether, as a result of elevated HMGA1 previously shown10, EndMT transcription 
factors Snail and Slug, and smooth muscle markers would be increased and endothelial markers 
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reduced.  BMPR2 siRNA resulted in an increase in HMGA1, Slug, αSMA and calponin mRNA, 
but there was no significant change in VE-cadherin or Snail (Fig 3A).  We confirmed loss of 
BMPR2 protein by immunoblot, and the associated elevation in HMGA1, increased Snail/Slug, 
αSMA and a prominent marker of EndMT, p-vimentin (Fig 3B,C).    PECAM-1 was reduced 
(Fig 3C) but not VE-cadherin (Fig 3B).  There was no change in another marker of EndMT, 
Twist (data not shown), suggesting that Snail/Slug are the critical transcription factors regulating 
EndMT resulting from loss of BMPR2.   
 
Increased αSMA in PAEC transfected with BMPR2 siRNA was visualized using 
immunofluorescent staining and confocal microscopy (Fig 4A).  Although VE-cadherin was not 
reduced by loss of BMPR2, we observed fragmented VE-cadherin immunostaining on the 
borders of PAECs suggesting an early breakdown of the junctions (Fig 4A).  Consistent with this 
was the change in morphology of a subset of siBMPR2 treated PAECs, from the typical 
cobblestone appearance to an elongated, spindle shape (Fig 4B).  Many of these elongated cells 
stained positively for αSMA (Fig 4C).  
 
EndMT changes induced by loss of BMPR2 require HMGA1 and Slug 
To determine whether HMGA1 was required for the EndMT induced by loss of BMPR2 we 
silenced BMPR2 and HMGA1, individually and in combination (Fig 5A).  As loss of BMPR2 
increases HMGA1 mRNA, we also found that loss of HMGA1 increased BMPR2 mRNA, 
suggesting a feedback mechanism (Fig 5A).  The increase in Slug mRNA seen with loss of 
BMPR2 was abolished by co-transfection with siRNA for HMGA1 and BMPR2, indicating that 
Slug is a target of elevated HMGA1 resulting from loss of BMPR2.  Similarly, the increase in 
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αSMA mRNA caused by loss of BMPR2 was significantly abrogated by knockdown of both 
BMPR2 and HMGA1.  Protein levels were similar to mRNA levels (Fig 5B).  To determine 
whether Slug was required for the increase in αSMA expression, we silenced BMPR2 and Slug, 
individually and in combination (Fig 5C).  We found that the increase in αSMA induced by loss 
of BMPR2 was completely prevented by concomitant knockdown of Slug mRNA, indicating that 
Slug is required for EndMT.  Similar to our observation with HMGA1, silencing Slug alone 
significantly increased BMPR2 mRNA suggesting that Slug plays a role in the feedback 
mechanism regulated by HMGA1 (Fig 5C).  
 
EndMT changes are not replicated by TGFβ treatment 
To determine whether loss of BMPR2 induces an increase in TGFβ signaling that is necessary 
for EndMT, we treated control PAECs with TGFβ2, previously implicated in EndMT24. TGFβ2 
signaling increased phosphorylated SMAD2 relative to total SMAD2 but loss of BMPR2 did not 
phosphorylate SMAD2 (Fig 6).  Moreover TGFβ2 increased HMGA1 but did not induce the 
EndMT related increase in Snail/Slug or αSMA (Fig 6). Taken together, our results show that 
EndMT changes in PAECs associated with loss of BMPR2 are not acting via TGFβ2 signaling. 
 
Mice lacking endothelial BMPR2 show changes consistent with EndMT 
To further characterize the relationship between reduced BMPR2 expression and EndMT, we 
studied EC-specific BMPR2 knockout mice (EC-BMPR2-KO) produced by breeding SCL-
CreERTM, R26LacZfl/fl and Bmpr2fl/fl mice and characterized in a previous study23.  They have no 
significant pulmonary hypertension at baseline, but develop exaggerated right ventricular 
systolic pressure and right ventricular hypertrophy following exposure to chronic hypoxia23 and 
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do not reverse pulmonary hypertension after recovery in room air 25.  Pulmonary ECs isolated 
from these mice show increased expression of HMGA1 and Slug at the mRNA and protein level, 
relative to wild type (WT) mice (Fig 7A, B).  While the increase in αSMA mRNA was small and 
not accompanied by a significant elevation in protein level, the increase in SM22α was 
particularly prominent both at mRNA and protein level (Fig 7A, B).  Immunofluorescence 
microscopy, however, showed a distinct increase in expression of αSMA in EC-BMPR2-KO 
relative to WT pulmonary ECs (Fig 7C).  Taken together, these findings suggest that loss of 
BMPR2 in pulmonary ECs is sufficient to promote features of EndMT in a transgenic mouse that 
develops more severe disease in response to a pulmonary hypertension-producing stimulus.  
 
Discussion 
Our study identifies a novel role for HMGA1 in promoting EndMT in PAH.  We show that 
PAECs highly expressing HMGA1 are prevalent in human PAH PA lesions.   Moreover, 
HMGA1 is upregulated by loss of BMPR2 in PAECs, as assessed either using siRNA to reduce 
BMPR2 in cultured human PAECs, or in transgenic mice with BMPR2 deleted in ECs.  
Downstream effectors of the increase in HMGA1 suggest an axis in which induction of Slug 
increases expression of αSMA and other SM genes including SM22α and calponin (see schema 
in Figure 8).  
 
Previous studies have documented elevated expression of HMGA1 in response to insults in 
human umbilical endothelial cells, with HMGA1 regulating genes induced by hypoxia26 and 
viral infection/inflammation27.  An elevation in HMGA1 is also a feature of angiogenesis in post-
ischemia brain ECs28.  Following identification of elevated HMGA1 mRNA in isolated PAECs 
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of patients with PAH by RNAseq10, we sought to determine the role of elevated HMGA1 
particularly with regard to EndMT in IPAH. 
 
HMGA1 co-localized primarily with endothelial and occasionally with smooth muscle markers 
in arteries with neointimal formation and plexogenic lesions.  While a previous study in mice 
used fate mapping to show αSMA-positive cells of endothelial lineage within the neointima, 
these cells comprised only a small sub-population7.  Similarly, not all neointimal cells in the 
human tissue expressed p-vimentin, a marker of EndMT.  Thus, it is possible that, at best, only a 
subset of PAECs contribute to the SM-like cells of the neointima as has been previously 
reported5,7.  The majority of PAECs may be transformed in a manner that impairs their ability to 
produce inhibitors of SMC proliferation, such as apelin6,29.   Consistent with this, we showed that 
PAH ECs produce less apelin when compared to donor controls5.  This transition without 
transformation is in keeping with mesenchymal changes noted in epithelial cells injured in 
fibrotic lung disease30.  These cells promote fibrosis but do not become fibroblasts.   
 
It is conceivable that once ECs fully undergo EndMT, HMGA1 levels fall and are not detectable 
by immunofluorescence.  This is in keeping with the drop in HMGA1 levels seen normally in 
tissue differentiation in development31,32,  but different from HMGA1 expression in cancer cells 
undergoing EMT, that remains highly expressed14.  
 
Clinical and experimental studies have linked reduced expression of BMPR2 to the development 
of PAH33,34.  Loss of BMPR2 in ECs confers susceptibility to apoptosis as well as impaired EC 
function as evidenced by angiogenesis and migration assays35,36.  We demonstrate a novel 
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relationship between loss of BMPR2 and increased expression of HMGA1 that is associated with 
morphologic changes and increased expression of Slug, αSMA and other SMC proteins.  These 
morphologic changes in cultured cells are in keeping with transmission electron microscopy 
studies of endothelial cells in the PAs from patients with PAH, that show increased 
microfilament bundles, consistent with cytoskeletal changes of EndMT37.  The high expression 
of HMGA1 in vWF-positive endothelial cells might suggests that HMGA1 can, as in cancer 
cells, contribute to the development of an apoptosis-resistant phenotype13,38. 
 
We previously related increased HMGA1 to elevated β-catenin10 resulting from loss of BMPR2.  
Other transcription factors or microRNAs (miRs) may be also involved.  We investigated several 
miRs that are reduced in PAH, including miR 2139,40 and miR 26a41, but they do not appear to 
regulate HMGA1 (data not shown).   
 
Co-transfection of siRNAs targeting HMGA1 and BMPR2 completely prevented the increase in 
Slug but only partially prevented the increase in αSMA at the mRNA and protein level.  The 
incomplete repression of αSMA by HMGA1 siRNA vs. Slug siRNA in the context of loss of 
BMPR2 was surprising. Perhaps another factor elicited by HMGA1 knockdown tempers the loss 
of Slug-related genes. HMGA1 was not previously identified as a regulator of αSMA, but it 
could potentiate serum response factor (SRF)-dependent transcription as has been shown for 
HMGA1 and SM22α42.   
 
Activation of BMPR2 signaling by BMP ligands reversed EMT in renal fibrosis43 and EndMT in 
cardiac fibrosis44.  In mesenchymal breast cancer cells, silencing HMGA1 promoted 
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mesenchymal-to-epithelial transition in conjunction with decreased proliferation, migration and 
invasion of the tumor cells14.  Stimulation of PAECs with BMP9 does repress HMGA1 (data not 
shown) suggesting that amplification of BMPR2 signaling via treatment with BMP945, FK50623  
or elafin46 may reverse EndMT.  
 
TGFβ signaling induces EndMT in experimental models of kidney47 and cardiac44 fibrosis and 
mature bovine PAECs in culture have been shown to undergo EndMT in response to TGFβ8.  
However, loss of BMPR2 did not result in activation of SMAD2, and TGFβ was insufficient to 
induce EndMT, highlighting a potentially unique feature of human PAECs.  
 
Gene expression changes consistent with EndMT were verified in mice with an inducible loss of 
BMPR2 in endothelial cells, and isolated pulmonary ECs from these mice showed a propensity 
to undergo EndMT in culture (Fig 7).  These mice showed mildly exaggerated pulmonary 
hypertension in chronic hypoxia23, and could not reverse pulmonary hypertension upon return to 
normoxia, in association with fewer distal vessels that were highly muscularized25.  Thus the 
susceptibility to EndMT may impair recovery from a pulmonary hypertensive state. 
 
In addition to EndMT, HMGA1 overexpression in cancer cells targets inflammatory genes, 
increases reactive oxygen species, and reduces mitochondrial DNA repair efficiency48,49, features 
that we observed in PAECs from patients with BMPR2 mutation25.  HMGA1 is thought to act as 
a transcriptional regulator, linking inflammatory pathways with oncogenic potential.  In PAH, 
HMGA1 may be the pivotal link between the “pro-inflammatory” state of PAECs and the 
breakdown of endothelial junctions due to EndMT, that permits inflammatory cell infiltration of 
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the vessel wall22,50 and propagation of the neointima.  Thus HMGA1 induces EndMT causing 
endothelial dysfunction and possible cellular contribution to occlusive vascular changes.  
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Table 1: Characteristics of Patients and Controls  
PAH Patients 
ID Assay 
Age 
(Yr) Gender Race Ethnicity Diagnosis 
BMPR2 
Mutation 
PAP 
s/d/m 
PVR 
(WU) 
6MW 
(m) PAH Medications 
PAH-01 
IHC 
WB 33 F White 
Non-
Hispanic FPAH Yes 87/29/48 9.74 288 
bosentan, treprostinil, 
sildenafil, epoprostenol 
PAH-02 
IHC     
WB 40 F White 
Non-
Hispanic IPAH No 84/26/47 N/A 294 
ambrisentan, sildenafil, 
iloprost, epoprostenol 
PAH-03 
IHC     
WB 27 M White 
Non-
Hispanic IPAH No 90/51/68 11.38 423.7 
bosentan, sildenafil, 
epoprostenol 
PAH-04 
IHC     
WB 49 F   White 
Non-
Hispanic      IPAH No 100/50/75 16.76 326.1 
Ambrisentan, sildenafil, 
epoprostenol 
PAH-05 
IHC 
 WB 56 F White 
Non-
Hispanic FPAH No 110/55/75 N/A 372.2 
epoprostenol, bosentan, 
ambrisentan, sildenafil 
PAH-06 IHC 62 F White 
Non-
Hispanic IPAH No 73/34/47 6.17 259.4 
epoprostenol, ambrisentan, 
bosentan 
PAH-07 IHC 33 F 
Black/ 
AA 
Non-
Hispanic FPAH Yes 75/33/48 15.57 326.1 
epoprostenol, bosentan, 
sildenafil, treprostinil 
PAH-08 IHC 58 F White 
Non-
Hispanic APAH No 127/59/77 N/A 1016 bosentan, treprostinil 
PAH-09 WB 16 F White 
Non-
Hispanic IPAH N/A 104/67/80 N/A 348.4 
bosentan, ambrisentan, 
epoprostenol, sildenafil, 
tresprostinil 
PAH-10 WB 29 F 
Black/ 
AA 
Non-
Hispanic IPAH No 63/29/41 N/A 339.2 
epoprostenol, ambrisentan, 
sildenafil 
PAH-11 WB 37 M White 
Non-
Hispanic FPAH Yes 119/51/77 14.22 309 
sildenafil, sitaxsentan, 
ambrisentan, epoprostenol, 
Imatinib (investi. 
medication), treprostinil 
PAH-12 WB 56 F White 
Non-
Hispanic      IPAH No 83/39/57 11.41 137.2 
sildenafil, ambrisentan, 
treprostinil 
PAH-13 WB 54 F White 
Non-
Hispanic IPAH N/A 100/45/60 N/A 296.3 
sildenafil, epoprostenol, 
ambrisentan, bosentan 
PAH-14 WB 55 F 
Black/ 
AA 
Non-
Hispanic IPAH No 89/41/53 12.29 273.4 
sildenafil, bosentan, 
epoprostenol 
PAH-15 WB 32 F White 
Non-
Hispanic IPAH No 68/38/49 15.34 238 bosentan, epoprostenol 
PAH-16 WB 41 F White 
Non-
Hispanic IPAH N/A 75/43/55 9.84 472.4 
sildenafil, bosentan, 
epoprostenol 
PAH-17 WB 56 M  White 
Non-
Hispanic IPAH No 125/50/75 9.58 234.7 tadalafil, bosentan 
PAH-18 WB 27 F  White 
Non-
Hispanic IPAH Yes 110/49/69 12.11 359.7 
sildenafil, 
tresprostinil,bosentan, 
iloprost 
PAH-19 WB 15 F White 
Non-
Hispanic IPAH No 175/66/102 25.24 387 sildenafil, epoprostenol 
PAH-20 WB 25 M White Hispanic IPAH No 65/15/36 N/A 510.5 
epoprostenol, sildenafil, 
treprostinil 
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Controls (Unused Donor Lungs) 
 
ID Assay 
Age 
(Yr) Gender Race Ethnicity Cause of Death 
CON-01 IHC 
WB 
 
11 M White Non-Hispanic Anoxia-Declared Brain Dead-Natural Causes 
(Hanging) 
CON-02 IHC WB 19 M 
Black or 
African 
American 
Not Reported Anoxia of brain 
CON-03 IHC 49 M White Unknown Intracranial hemorrhage 
CON-04 IHC 41 F White Non-Hispanic Grade 4 subarachnoid hemorrhage, ruptured 
anterior cerebral artery aneurysm 
CON-05 IHC 26 M White Non-Hispanic Cerebrovascular/Stroke 
CON-06 IHC 14 M White Non-Hispanic Cardiac Arrest secondary to Diabetic 
Ketoacidosis 
CON-07 WB 55 M White Non-Hispanic Anoxia/cardiovascular/natural causes 
CON-08 WB 24 M White Non-Hispanic Cerebrovascular Stroke/Intracranial 
hemorrhage 
CON-09 WB 40 F White Non-Hispanic Extensive intracranial injury/subarachnoid 
hemorrhage secondary to MVA 
CON-10 WB 25 M White Non-Hispanic Intracranial Hemorrhage 
CON-11 WB 52 F White Unknown Hypoxic brain death secondary to PEA arrest 
CON-12 WB 1 M White Non-Hispanic Anoxia/Drowning 
CON-13 WB 57 F White Non-Hispanic Acute Myocardial Infarction 
CON-14 WB 45 F White Non-Hispanic Subarachnoid hemorrhage 
CON-15 WB 56 F White Non-Hispanic CVA 
CON-16 WB 43 M White  Non-Hispanic Fatal gun shot to head 
 
Hemodynamic data from catheterization were obtained from studies performed closest to 
transplantation. PAH medications are listed according to total drug exposure during treatment 
period of follow-up, not necessarily in combination.  
IHC, Immunohistochemistry 
WB, Western blots  
N/A – data not available 
IPAH, Idiopathic PAH 
CIRCULATIONAHA/2014/013707/R2, page 27 
HPAH, hereditary PAH 
PAP, pulmonary artery pressure (mmHg); s: systolic, d: diastolic, m: mean 
PVR, pulmonary vascular resistance (dynes/seccm-5) (Baseline Fick PVR) 
6MW, distance (m) walked in 6 minutes  
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Figure Legends 
 
Figure 1: Elevated HMGA1 protein expression in patients with PAH 
(A) Western immunoblot and densitometric quantification of HMGA1 protein isolated from 
cultured PAECs from donor controls and patients with PAH with or without BMPR2 mutation. 
Scatterplots indicate mean±SEM.  *P<0.05 compared to control by Kruskal-Wallis test with 
Dunn’s post hoc testing.  (B) Representative immunohistochemistry for HMGA1 (brown) and 
hematoxylin counterstain (blue-purple) in small peripheral (left panels) and larger pre-acinar 
pulmonary arteries (PAs) from controls and patients with PAH.  In PAs from patients with PAH, 
HMGA1 was observed primarily in the endothelium and neointimal cells adjacent to the 
endothelium lining the vessel wall (arrows).  The expression of HMGA1 was not detected by 
immunoperoxidase in the PA endothelium or the vascular wall from controls.  Scale bar=50µm 
for the left images; 100µm for the center images and 25µm for the inserts.  (C) Expression of 
HMGA1 is especially pronounced in the endothelium and neointimal cells of an occluded artery 
and in the endothelium of a plexiform lesion (arrows).  Scale bar= 100µm and 25µm for the 
inserts.  (D) Pulmonary tissues from patients with PAH were analyzed for histopathological signs 
of vascular disease in relation to HMGA1 expression.  The degree of vascular disease was scored 
as absent (Normal); enhanced muscularization or medial hypertrophy (Musc); presence of 
neointimal hyperplasia (Neoint) or complete occlusion (Occlud).  Quantification of staining by 
vessel size is shown as mean±SEM for multiple vessels from n=3 patients with PAH.  
 
Figure 2:  HMGA1 localizes to PAECs in PAH, but not in controls  
Representative confocal images of different size pulmonary arteries in tissue sections from donor 
controls and patients with PAH stained for vWF (red), SM22α (green), HMGA1 (white) and 
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DRAQ7 (blue).  HMGA1 co-localizes with endothelial cells (arrows) and neointimal cells (arrow 
heads) in tissues from patients with PAH, while the expression of HMGA1 is limited to rare cells 
in the PA adventitia from control donors (arrow heads).  Scale bar=25µm (left column) and 
50µm (middle and right columns). 
 
Figure 3:  BMPR2 silencing in control PAECs induces increased HMGA1 and EndMT 
markers 
Commercially available PAECs were transfected with siRNA for BMPR2 (B2) or control non-
targeting siRNA (Con).  (A) Gene expression changes were assessed by qPCR after 72h.  (B) 
Representative immunoblot and densitometric quantification of protein expression assessed 7 
days after siRNA transfection. Snail/Slug indicates an antibody recognizing both Snail and Slug 
proteins. (C) Representative immunoblot and densitometric quantification of protein expression 
assessed 7 days after siRNA transfection. Boxplots indicate minimum, maximum and median for 
n=9 (A and B). Scatterplots indicate mean±SEM for n=3 (C).  *P<0.05, **P<0.01, ***P<0.001, 
****P<0.0001 compared to respective Con by Student’s t-test.  
 
Figure 4: Silencing of BMPR2 enhances the expression of αSMA in PAECs 
Commercially available PAECs were transfected with siRNAs targeting BMPR2 or non-
targeting control siRNA and analyzed after 7 days.  (A) Cells were analyzed by 
immunofluorescence for the expression of VE-cadherin (green), αSMA (red) and nuclei (DAPI, 
blue).  Scale Bar=50µm. Graph indicates quantification of αSMA immunofluorescence relative 
to DAPI.  Bars indicate mean±SEM, n=5.  *P<0.05.  (B) Representative phase contrast light 
microscopy images showing typical cobblestone morphology of control siRNA transfected 
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PAECs vs. a monolayer including cells with an elongated spindle shape (arrows) in BMPR2 
siRNA transfected PAECs.  Scale Bar=100µm.  (C) Immunofluorescence microscopy showing 
an elongated PAEC expressing αSMA (red) from BMPR2 siRNA transfected PAECS compared 
to control siRNA transfected PAECs.  Scale Bar=50µm. 
 
Figure 5:  HMGA1 and Slug are necessary for EndMT gene expression changes induced by 
loss of BMPR2 
Commercially available PAECs were transfected using non-targeting siRNA (Con) or siRNA 
targeting BMPR2 (B2), HMGA1 (H), BMPR2 and HMGA1 (B2+H), Slug (S), or Slug and 
BMPR2 (B2+S).  mRNA normalized to β-actin was assessed by qPCR 72h after transfection.   
(A) Gene expression levels of BMPR2, HMGA1, Slug and αSMA following siRNA for BMPR2 
±HMGA1. (B) Representative immunoblot and densitometric analysis of BMPR2, HMGA1, 
Snail/Slug and αSMA protein expression normalized to GAPDH 72h following siRNA for 
BMPR2±HMGA1.  (C) Gene expression levels of BMPR2, Slug and αSMA following siRNA 
for BMPR2±Slug. Boxplots indicate minimum, maximum and median for n=9 (A and C). 
Scatterplots indicate mean±SEM for n=3 (in B). *P<0.05, **P<0.01, ***P<0.001, ****P<0.0001 
by one-way ANOVA relative to Con. #P<0.05, ##P<0.01, ###P<0.001, ####P<0.0001 by one-
way ANOVA relative to siRNA (B2) treatment.  In Panel B, P<0.05, by one-way ANOVA with 
selected post-hoc comparisons of B2 vs. Con siRNA (§) and B2+H vs. B2 siRNA (+). 
 
Figure 6:  TGFβ2 does not induce EndMT in PAECs 
Representative immunoblot with densitometric analysis of HMGA1, Snail/Slug, αSMA and 
pSMAD2 in control PAECs transfected with control (Con) or BMPR2 (B2) siRNA and treated 
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with vehicle or TGFβ2 (10 ng/ml) for 5 days, starting 48h after transfection.  Boxplots indicate 
minimum, maximum and median for n=6 per group. Scatterplot indicates mean±SEM for n=3. 
*P<0.05, **P<0.01, ***P<0.001 vs. non-targeting non TGFβ2-treated siRNA control by one-
way ANOVA. 
 
Figure 7:  Pulmonary ECs from mice lacking endothelial BMPR2 show changes consistent 
with EndMT 
Pulmonary ECs isolated from mice with BMPR2 deleted in ECs (BMPR2 KO or KO) or wild 
type (WT) controls were assessed for EndMT changes at the mRNA (A) and protein (B) levels, 
and by immunofluorescence microscopy (C).  Pulmonary ECs were isolated from three mice, 
pooled and cultured.  Assays were conducted at passages 3-8.  (A) mRNA assessed by qPCR, 
n=6.  (B) Representative immunoblot and densitometric quantification of WT or BMPR2 KO 
pulmonary ECs, n=3 or 4 as shown in the two blots (passages 2-5).  (C) Representative 
immunofluorescence images by confocal microscopy of WT or BMPR2 KO mouse pulmonary 
ECs for VE-cadherin (green) and αSMA (red).  Nuclei stained with DAPI (blue).  Scale 
bar=50µm.  Quantification of αSMA fluorescence is depicted below, n=3. Boxplots indicate 
minimum, maximum and median. Scatterplot indicates mean±SEM. *P<0.05, **P<0.01, 
***P<0.001, ****P<0.0001 vs. control or WT by Student’s t-test.  
 
Figure 8: Proposed model: Loss of BMPR2 promotes EndMT via HMGA1 
Loss of BMPR2 in PAECs leads to heightened expression of HMGA1, which increases the 
transcription factor Slug.  HMGA1 binds to DNA and may promote binding of additional pro-
EndMT transcription factors.  Expression of smooth muscle genes, such as αSMA, SM22α, 
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calponin and p-vimentin are increased and  the endothelial gene PECAM1 is decreased, 
reflecting a mesenchymal phenotype.  
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Supplemental Table 1: Primers Used 
Gene (HUMAN) Primer 
HMGA1 F – GCTGGTAGGGAGTCAGAAGGA R - TGGTGGTTTTCCGGGTCTTG 
SLUG F – CGAACTGGACACACATACAGTG R - CTGAGGATCTCTGGTTGTGGT 
SNAIL F – TCGGAAGCCTAACTACACAGCGA R - AGATGAGCATTGGCAGCGAG 
αSMA F – CTATGAGGGCTATGCCTTGCC R - GCTCAGCCAGTAGTAACGAAGGA 
1 VE-CADHERIN F – TTGGAACCAGATGCACATTGAT R – TCTTGCGACTCACGCTTGAC 
CALPONIN F – CTGTCAGCCGAGGTTAAGAAC R - GAGGCCGTCCATGAAGTTGTT 
BMPR2 F – CTGCGGCTGCTTCGCAGAAT R - TGGTGTTGTGTCAGGAGGTGG 
β-ACTIN F – CATGCCATCCTGCGTCTGGA R - CCGTGGCCATCTCTTGCTCG 	  
Gene (MOUSE) Primer 
HMGA1 F – GGTCGGGAGTCAGAAAGAGC R – ATTCTTGCTTCCCTTTGGTCG 
SLUG F – CAGCGAACTGGACACACACA R – ATAGGGCTGTATGCTCCCGAG 
αSMA F – CCCAGACATCAGGGAGTAATGG R – TCTATCGGATACTTCAGCGTCA 
SM22α F – CCAACAAGGGTCCATCCTACG R – ATCTGGGCGGCCTACATCA 
BMPR2 F – TCGCATCTGCCATTTGTCCT R - TAGGAGGCTGCTCTTCGTCT 
β-ACTIN F – ATGTGGATCAGCAAGCAGGA R - AAGGGTGTAAAACGCAGCTCA 	  
